Literature DB >> 9379077

Recent advances in the immunology of xenotransplantation.

T Takahashi1, S Saadi, J L Platt.   

Abstract

The transplantation of tissue and organs between individuals of different species, that is xenotransplantation, engenders a variety of severe immune responses. Xenogeneic immune responses mediated by naturally occurring antibodies and complement lead to hyperacute and acute vascular rejection of vascularized organ grafts and may also cause vascular rejection of cell and tissue grafts. Under some circumstances, however, a vascularized organ graft may evade humoral rejection despite the presence of antidonor antibodies in the circulation of the recipient; this condition is called accommodation. Xenogeneic immune responses mediated by T-lymphocytes and natural killer cells may cause acute cellular rejection. The extent to which cellular rejection of xenografts resembles cellular rejection of allografts remains to be determined. New insights into the molecular mechanisms underlying the immune responses to xenotransplantation have shed new light on the pathogenesis of immunological disease and have allowed the development of specific immunomodulatory strategies that may facilitate clinical application of xenotransplantation.

Entities:  

Mesh:

Year:  1997        PMID: 9379077     DOI: 10.1007/BF02786395

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  146 in total

1.  COMPLEMENT FIXATION DURING HOMOGRAFT REJECTION.

Authors:  D S CLARK; H GEWURZ; R A GOOD; R L VARCO
Journal:  Surg Forum       Date:  1964

2.  Acute destruction by humoral antibody of rat skin grafted to mice.

Authors:  C A Baldamus; I F McKenzie; H J Winn; P S Russell
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

3.  Experiences with known ABO-mismatched renal transplants.

Authors:  A D Bannett; R F McAlack; R Raja; A Baquero; M Morris
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

4.  A primate model of hyperacute renal allograft rejection.

Authors:  G J Busch; A C Martins; N K Hollenberg; R E Wilson; R W Colman
Journal:  Am J Pathol       Date:  1975-04       Impact factor: 4.307

5.  Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection.

Authors:  M L Blakely; W J Van der Werf; M C Berndt; A P Dalmasso; F H Bach; W W Hancock
Journal:  Transplantation       Date:  1994-11-27       Impact factor: 4.939

6.  Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans.

Authors:  A H Good; D K Cooper; A J Malcolm; R M Ippolito; E Koren; F A Neethling; Y Ye; N Zuhdi; L R Lamontagne
Journal:  Transplant Proc       Date:  1992-04       Impact factor: 1.066

7.  Evaluation of cyclosporine, mycophenolate mofetil, and Brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation.

Authors:  Y Fujino; T Kawamura; D A Hullett; H W Sollinger
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

8.  Specific intravenous carbohydrate therapy. A new concept in inhibiting antibody-mediated rejection--experience with ABO-incompatible cardiac allografting in the baboon.

Authors:  D K Cooper; Y Ye; M Niekrasz; M Kehoe; M Martin; F A Neethling; S Kosanke; L E DeBault; G Worsley; N Zuhdi
Journal:  Transplantation       Date:  1993-10       Impact factor: 4.939

9.  In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats.

Authors:  S Matsuo; S Ichida; H Takizawa; N Okada; L Baranyi; A Iguchi; B P Morgan; H Okada
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin.

Authors:  S V Jooste; R B Colvin; H J Winn
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  2 in total

1.  Heart xenograft survival with chimeric pig donors and modest immune suppression.

Authors:  William E Beschorner; Debra L Sudan; Stanley J Radio; Tianyu Yang; Kenneth L Franco; Arthur C Hill; C Carson Shearon; Scott C Thompson; Robert S Dixon; Noel D Johnson; Charles A Kuszynski; Ronald J Rubocki; Kelly F Lechtenberg; Aurelio Matamoros; Timothy C Goertzen; Ira J Fox; Alan N Langnas
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

2.  Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.

Authors:  Go Itakura; Yoshiomi Kobayashi; Soraya Nishimura; Hiroki Iwai; Morito Takano; Akio Iwanami; Yoshiaki Toyama; Hideyuki Okano; Masaya Nakamura
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.